"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
Descriptor ID |
D008687
|
MeSH Number(s) |
D02.078.370.141.450
|
Concept/Terms |
Metformin- Metformin
- Dimethylbiguanidine
- Dimethylguanylguanidine
|
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in this website by year, and whether "Metformin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 2 | 1 | 3 |
2006 | 1 | 0 | 1 |
2008 | 1 | 1 | 2 |
2010 | 1 | 0 | 1 |
2011 | 1 | 1 | 2 |
2012 | 1 | 0 | 1 |
2013 | 2 | 0 | 2 |
2014 | 1 | 1 | 2 |
2015 | 2 | 0 | 2 |
2016 | 1 | 3 | 4 |
2017 | 1 | 0 | 1 |
2018 | 2 | 0 | 2 |
2019 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metformin" by people in Profiles.
-
Hsia SH, Duran P, Lee ML, Davidson MB. Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study. J Diabetes. 2020 Jan; 12(1):91-94.
-
Chia YMF, Teng TK, Tay WT, Anand I, MacDonald MR, Yap J, Chandramouli C, Richards AM, Tromp J, Ouwerkerk W, Ling LH, Lam CSP. Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus. Eur J Heart Fail. 2019 05; 21(5):685-688.
-
Schexnayder C, Broussard K, Onuaguluchi D, Poché A, Ismail M, McAtee L, Llopis S, Keizerweerd A, McFerrin H, Williams C. Metformin Inhibits Migration and Invasion by Suppressing ROS Production and COX2 Expression in MDA-MB-231 Breast Cancer Cells. Int J Mol Sci. 2018 Nov 21; 19(11).
-
Han J, Saraf SL, Molokie RE, Gordeuk VR. Use of metformin in patients with sickle cell disease. Am J Hematol. 2019 01; 94(1):E13-E15.
-
Tao Y, Chen B, Zhang BH, Zhu ZJ, Cai Q. Occurrence, Impact, Analysis and Treatment of Metformin and Guanylurea in Coastal Aquatic Environments of Canada, USA and Europe. Adv Mar Biol. 2018; 81:23-58.
-
Jiménez-Ramírez FJ, Castro LM, Ortiz C, Concepción J, Renta JY, Morales-Borges RH, Miranda-Massari JR, Duconge J. Role of treatment-modifying MTHFR677C>T and 1298A>C polymorphisms in metformin-treated Puerto Rican patients with type-2 diabetes mellitus and peripheral neuropathy. Drug Metab Pers Ther. 2017 03 01; 32(1):23-32.
-
Bobart SA, Gleason B, Martinez N, Norris K, Williams SF. Euglycemic Ketoacidosis Caused by Sodium-Glucose Cotransporter 2 Inhibitors: A Case Report. Ann Intern Med. 2016 Oct 04; 165(7):530-532.
-
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013. Diabetes Care. 2017 Apr; 40(4):468-475.
-
Boulin M, Diaby V, Tannenbaum C. Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada. PLoS One. 2016; 11(9):e0162951.
-
El-Zaher AA, Elkady EF, Elwy HM, Saleh MA. Simultaneous Determination of Metformin, Glipizide, Repaglinide, and Glimepiride or Metformin and Pioglitazone by a Validated LC Method: Application in the Presence of Metformin Impurity (1-Cyanoguanidine). J AOAC Int. 2016 Jul; 99(4):957-963.